Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly

AbbVie execs have finally gotten around to doing what a host of analysts managed to accomplish long ago: writing down the value of their once much-vaunted cancer drug Rova-T.